CTLA4 (CD152) modulates the Th subset response and alters the course of experimental Leishmania major infection - PubMed (original) (raw)
CTLA4 (CD152) modulates the Th subset response and alters the course of experimental Leishmania major infection
B Saha et al. Eur J Immunol. 1998 Dec.
Free article
Abstract
Since both the nature and the amplitude of an antigen-specific T cell response are dependent on co-stimulatory signals, we have investigated the role of CD28/CD152-mediated T cell co-stimulation in the regulation of experimental cutaneous leishmaniasis. CD28-deficient mice and their wild-type littermates are equally susceptible to Leishmania major infection. Whole anti-CD152 antibody significantly exacerbates the disease while anti-CD152 Fab ameliorates the disease in genetically susceptible BALB/c mice but not in C57BL/6, a resistant strain. The anti-CD152-induced exacerbation of the disease is accompanied by increased IL-4-secreting cell number, diminished parasite-specific delayed-type hypersensitivity (DTH) response and augmented anti-2,4,6-trinitrophenyl (TNP) IgG1 in response to TNP-leishmanial antigen crude soluble antigen (CSA), suggesting an exaggerated Th2 type of response. Anti-CD152 Fab-mediated amelioration of the disease is associated with increased IFN-gamma-secreting cell number, increased parasite-specific DTH response and enhanced IgG2a isotype in response to TNP-CSA suggesting a Th1 type of response. Unlike TNP-CSA, TNP-keyhole limpet hemocyanin does not induce the change in Ig isotype, indicating that the immunomodulatory effect of anti-CD152 is antigen specific. Anti-CD152 antibody-induced early change in Th subsets suggests an important role for CD152 in determining the course of L. major infection, perhaps by alteration of Th subset differentiation.
Similar articles
- Interleukin-4-independent acceleration of cutaneous leishmaniasis in susceptible BALB/c mice following treatment with anti-CTLA4 antibody.
Heinzel FP, Maier RA Jr. Heinzel FP, et al. Infect Immun. 1999 Dec;67(12):6454-60. doi: 10.1128/IAI.67.12.6454-6460.1999. Infect Immun. 1999. PMID: 10569763 Free PMC article. - Differential effects of blockade of CD28-B7 on the development of Th1 or Th2 effector cells in experimental leishmaniasis.
Corry DB, Reiner SL, Linsley PS, Locksley RM. Corry DB, et al. J Immunol. 1994 Nov 1;153(9):4142-8. J Immunol. 1994. PMID: 7523517 - Interleukin-12 is capable of generating an antigen-specific Th1-type response in the presence of an ongoing infection-driven Th2-type response.
Schopf LR, Bliss JL, Lavigne LM, Chung CL, Wolf SF, Sypek JP. Schopf LR, et al. Infect Immun. 1999 May;67(5):2166-71. doi: 10.1128/IAI.67.5.2166-2171.1999. Infect Immun. 1999. PMID: 10225870 Free PMC article. - Differentiation, regulation, and death of T helper cell subsets during infection with Leishmania major.
Scott P. Scott P. Immunol Res. 1998;17(1-2):229-38. doi: 10.1007/BF02786447. Immunol Res. 1998. PMID: 9479584 Review.
Cited by
- Unraveling the Role of Immune Checkpoints in Leishmaniasis.
de Freitas E Silva R, von Stebut E. de Freitas E Silva R, et al. Front Immunol. 2021 Mar 11;12:620144. doi: 10.3389/fimmu.2021.620144. eCollection 2021. Front Immunol. 2021. PMID: 33776999 Free PMC article. Review. - CTLA-4 down-regulates the protective anticryptococcal cell-mediated immune response.
McGaha T, Murphy JW. McGaha T, et al. Infect Immun. 2000 Aug;68(8):4624-30. doi: 10.1128/IAI.68.8.4624-4630.2000. Infect Immun. 2000. PMID: 10899865 Free PMC article. - LmjF.36.3850, a novel hypothetical Leishmania major protein, contributes to the infection.
Zutshi S, Sarode AY, Ghosh SK, Jha MK, Sudan R, Kumar S, Sadhale LP, Roy S, Saha B. Zutshi S, et al. Immunology. 2021 Aug;163(4):460-477. doi: 10.1111/imm.13331. Epub 2021 Apr 26. Immunology. 2021. PMID: 33764520 Free PMC article. - Interleukin-4-independent acceleration of cutaneous leishmaniasis in susceptible BALB/c mice following treatment with anti-CTLA4 antibody.
Heinzel FP, Maier RA Jr. Heinzel FP, et al. Infect Immun. 1999 Dec;67(12):6454-60. doi: 10.1128/IAI.67.12.6454-6460.1999. Infect Immun. 1999. PMID: 10569763 Free PMC article. - Immunotherapeutic Strategies as Potential Treatment Options for Cutaneous Leishmaniasis.
Lafleur A, Daffis S, Mowbray C, Arana B. Lafleur A, et al. Vaccines (Basel). 2024 Oct 17;12(10):1179. doi: 10.3390/vaccines12101179. Vaccines (Basel). 2024. PMID: 39460345 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources